Understanding Humate-P Potency Values: A Clinical Guide for Pharmacists

The appropriate dispensing and administration of Humate-P requires a sophisticated understanding of its dual potency labeling system and the clinical indication for which it is prescribed. This comprehensive analysis addresses the critical challenges pharmacists face when prescribers provide doses in international units without specifying whether the dosing should be based on von Willebrand factor ristocetin cofactor activity (VWF:RCo) or Factor VIII coagulant activity (FVIII:C). The distinction between these two potency measurements is not merely academic but represents a fundamental aspect of patient safety and therapeutic efficacy. Recent clinical studies have demonstrated that inappropriate interpretation of dosing units can lead to significant under-dosing or over-dosing, with potentially serious clinical consequences including inadequate hemostasis or increased risk of thrombotic complications^{1, 10, 11}.

What is von Willebrand factor ristocetin cofactor activity?

Von Willebrand factor ristocetin cofactor activity (VWF:RCo) is a laboratory assay that measures the functional activity of von Willebrand factor (VWF) in plasma. Specifically, it evaluates VWF's ability to bind to platelet glycoprotein Ib (GPIb) receptors in the presence of the antibiotic ristocetin, which induces platelet agglutination. The degree of platelet agglutination in this assay is proportional to the VWF activity in the plasma sample, reflecting its role in platelet adhesion and blood clotting.

When a prescriber writes a dose of Humate-P in “international units” without specifying the basis, what is the primary risk for the pharmacist?

Ans: Misinterpreting whether the dose refers to VWF:RCo or FVIII

💡 The key issue is that Humate-P uses two potency systems: von Willebrand factor ristocetin cofactor activity (VWF:RCo) and Factor VIII coagulant activity (FVIII:C). If the prescriber doesn’t clarify, the pharmacist could misinterpret which one the IU refers to, leading to under- or overdosing.

What are the possible clinical consequences if a pharmacist misinterprets the potency units of Humate-P?

Ans: The patient may experience either inadequate hemostasis or thrombotic complications.

Too little → inadequate hemostasis (bleeding risk)
Too much → thrombotic complications (clotting risk)

Humate-P Composition and Dual Potency Labeling System

Humate-P represents a sophisticated plasma-derived concentrate containing both antihemophilic factor VIII and von Willebrand factor in a carefully controlled ratio. The product maintains an average VWF:RCo to FVIII ratio of approximately 2.4 to 1, which distinguishes it from other factor concentrates and necessitates specific consideration in clinical dosing decisions^{1, 3, 6}. This ratio was deliberately engineered to provide therapeutic levels of von Willebrand factor without causing excessive accumulation of Factor VIII, a consideration that has become increasingly important as clinicians have recognized the thrombotic risks associated with supranormal Factor VIII levels^{5, 10}.

The dual labeling system employed for Humate-P reflects the product's dual therapeutic applications. Each vial is labeled with both VWF:RCo activity and FVIII:C activity, expressed in international units. The standard vial sizes include 600 IU VWF:RCo with 250 IU FVIII:C, 1200 IU VWF:RCo with 500 IU FVIII:C, and 2400 IU VWF:RCo with 1000 IU FVIII:C, all maintaining the consistent 2.4:1 ratio^{6, 7}. This labeling approach acknowledges that the appropriate dosing metric depends entirely on the clinical indication for which the product is being used, requiring pharmacists to possess a thorough understanding of both the patient's diagnosis and the therapeutic objectives.

The manufacturing process for Humate-P involves purification from the cold insoluble fraction of pooled human fresh-frozen plasma, resulting in a product with high purity and low quantities of non-factor proteins¹⁵. The fibrinogen content is maintained at less than or equal to 0.2 mg/mL, and the overall purity profile exceeds that of traditional cryoprecipitate preparations¹⁵. This purification process preserves the natural complex between von Willebrand factor and Factor VIII while removing potentially immunogenic or thrombogenic contaminants. Understanding this manufacturing background helps pharmacists appreciate why the product maintains its specific potency ratio and why this ratio has clinical significance beyond mere convenience.

The international standardization of potency measurements ensures consistency across different lots and manufacturers, but it also creates the potential for confusion when prescribers fail to specify which potency measurement should guide dosing. The World Health Organization has established reference standards for both VWF:RCo and FVIII:C activities, and these standards are used to calibrate the potency measurements on Humate-P vials¹. However, the clinical application of these standardized measurements requires careful attention to the specific indication and the corresponding therapeutic targets for each component of the complex.

Indication-Driven Dosing Principles

The fundamental principle underlying appropriate Humate-P dosing is that the clinical indication determines which potency measurement should guide dose calculations. For patients with von Willebrand disease, the primary therapeutic objective is to correct the deficiency or dysfunction of von Willebrand factor, making VWF:RCo the appropriate dosing metric^{1, 5, 7}. Conversely, for patients with hemophilia A, the primary therapeutic objective is to correct Factor VIII deficiency, making FVIII:C the appropriate dosing metric^{3, 4}. This distinction is not arbitrary but reflects the different pathophysiological mechanisms underlying these two bleeding disorders and the different therapeutic targets required for effective hemostasis.

When prescribers provide doses in international units without specifying the potency basis, pharmacists must rely on their clinical knowledge and communication skills to ensure appropriate interpretation. The indication for Humate-P use should always be clearly documented in the medical record, and pharmacists should verify this information before dispensing^{7, 8}. In cases where the indication is unclear or where there might be ambiguity about the intended dosing basis, direct communication with the prescriber is essential to prevent medication errors and ensure optimal patient outcomes.

The clinical evidence supporting indication-driven dosing comes from multiple prospective studies that have demonstrated the importance of targeting appropriate levels of the relevant coagulation factor. In surgical prophylaxis studies for von Willebrand disease, dosing based on VWF:RCo activity achieved excellent hemostatic efficacy in 95% of patients, with minimal adverse events¹. These studies used specific target levels for VWF:RCo activity and adjusted doses accordingly, demonstrating that the choice of dosing metric has direct clinical consequences. Similarly, studies in hemophilia A have shown that dosing based on FVIII:C activity provides predictable hemostatic responses when appropriate target levels are achieved^{3, 4}.

The pharmacokinetic properties of VWF:RCo and FVIII:C also differ significantly, further supporting the importance of indication-driven dosing. VWF:RCo has a longer half-life than FVIII:C, and the presence of von Willebrand factor actually protects Factor VIII from degradation, extending its half-life^{9, 10, 11}. This interaction means that repeated dosing based on VWF:RCo activity will result in different Factor VIII accumulation patterns compared to dosing based directly on FVIII:C activity. Understanding these pharmacokinetic differences helps pharmacists appreciate why the choice of dosing metric affects not only immediate therapeutic outcomes but also the risk of accumulation and potential adverse effects.

Surgical Prophylaxis in Von Willebrand Disease

Surgical prophylaxis in patients with von Willebrand disease represents one of the most critical applications of Humate-P, and it exemplifies the importance of VWF:RCo-based dosing. The clinical evidence supporting this approach comes from two landmark prospective studies conducted in the United States and European Union, which collectively enrolled 62 patients undergoing various surgical procedures¹. These studies established that pharmacokinetically guided dosing based on VWF:RCo activity could achieve and maintain appropriate hemostatic levels while minimizing the risk of Factor VIII accumulation and associated thrombotic complications.

The dosing strategy for surgical prophylaxis involves calculation of both loading and maintenance doses based on individual patient pharmacokinetic parameters, baseline VWF:RCo levels, and target therapeutic levels^{1, 5, 8}. For major surgery, the target VWF:RCo level is typically 100 IU/dL, while minor surgery requires target levels of 50-60 IU/dL^{3, 5, 8}. These targets are based on extensive clinical experience demonstrating that VWF:RCo levels below these thresholds are associated with increased bleeding risk, while levels significantly above these thresholds may increase the risk of thrombotic complications without providing additional hemostatic benefit.

The calculation of loading doses for surgical prophylaxis requires knowledge of the patient's individual in vivo recovery (IVR), which represents the relationship between the administered dose and the resulting plasma level increase^{1, 3}. When individual IVR data are available, the loading dose can be calculated using the formula: (Target VWF:RCo - Baseline VWF:RCo) × Body Weight (kg) / IVR = Required IU VWF:RCo^{3, 8}. In situations where individual IVR cannot be determined, a standard assumption of 2.0 IU/dL per IU/kg is recommended^{1, 3}. This standardized approach provides a reasonable starting point for dose calculations while acknowledging that individual variation may require dose adjustments based on monitoring results.

Maintenance dosing for surgical prophylaxis typically involves administration of half the loading dose every 8-12 hours, with the frequency determined by individual pharmacokinetic parameters and monitoring results^{1, 5, 8}. The duration of treatment varies according to the type and complexity of surgery, with minor procedures typically requiring 2-4 days of treatment and major procedures potentially requiring more than 4 days^{1, 8}. Throughout the treatment period, monitoring of both VWF:RCo and FVIII:C levels is essential to ensure therapeutic efficacy while preventing excessive accumulation of either factor.

The clinical outcomes achieved with VWF:RCo-based dosing in surgical prophylaxis have been consistently excellent across multiple studies. The pooled analysis of the US and EU surgical studies demonstrated overall hemostatic efficacy (rating of excellent/good) in 95% of patients, with only 13% experiencing possibly related adverse events¹. One serious adverse event (pulmonary embolism) was reported, highlighting the importance of monitoring for thrombotic complications, particularly in patients receiving multiple doses or those with additional risk factors for thrombosis^{1, 5}.

Hemophilia A Treatment Considerations

The treatment of hemophilia A with Humate-P requires a fundamentally different dosing approach compared to von Willebrand disease management, with Factor VIII coagulant activity (FVIII:C) serving as the primary dosing metric. The pharmacokinetic principle underlying hemophilia A treatment is that one international unit of Factor VIII activity per kilogram of body weight increases the circulating FVIII:C level by approximately 2.0 IU/dL^{3, 4}. This predictable relationship allows for precise dose calculations based on the patient's weight, the severity of bleeding, and the target Factor VIII level required for effective hemostasis.

The dosing recommendations for hemophilia A vary significantly based on the severity and location of bleeding. Minor hemorrhages typically require a loading dose of 15 IU FVIII:C/kg to achieve a plasma level of approximately 30% of normal, with one infusion often being sufficient⁴. Moderate hemorrhages require higher initial levels, with loading doses of 25 IU FVIII:C/kg targeting plasma levels of approximately 50% of normal, followed by maintenance doses to sustain levels at 30% of normal for several days⁴. Life-threatening hemorrhages necessitate the most aggressive approach, with initial doses of 40-50 IU FVIII:C/kg targeting plasma levels of 80-100% of normal, maintained at these levels for seven days before transitioning to lower maintenance levels⁴.

The selection of Humate-P for hemophilia A treatment, rather than a pure Factor VIII concentrate, is typically reserved for specific situations where the von Willebrand factor component provides additional therapeutic benefit. Some patients with hemophilia A may have concurrent von Willebrand factor deficiency or dysfunction, making the combination product advantageous^{3, 13}. Additionally, some clinicians prefer Humate-P for patients who have developed inhibitors to other Factor VIII products, although this application requires careful monitoring and specialized expertise³.

When using Humate-P for hemophilia A treatment, pharmacists must be particularly attentive to the Factor VIII content rather than the VWF:RCo content. The 2.4:1 ratio means that each vial contains significantly more VWF:RCo activity than FVIII:C activity, and dosing based on the VWF:RCo content would result in substantial underdosing of Factor VIII^{6, 7}. For example, a 70-kg patient requiring a moderate hemorrhage dose of 25 IU FVIII:C/kg would need 1,750 IU of Factor VIII activity, which would require 3.5 vials of the 500 IU FVIII:C strength, providing the necessary Factor VIII while simultaneously delivering approximately 4,200 IU of VWF:RCo activity.

The monitoring requirements for hemophilia A treatment with Humate-P include regular assessment of Factor VIII levels to ensure therapeutic efficacy and prevent excessive accumulation. The presence of von Willebrand factor in the concentrate can actually extend the half-life of Factor VIII by protecting it from degradation, potentially leading to higher than expected Factor VIII levels with repeated dosing^{9, 10, 11}. This interaction requires careful monitoring and possible dose adjustments to prevent excessive Factor VIII accumulation while maintaining therapeutic efficacy.

Pharmacokinetic and Pharmacodynamic Considerations

The pharmacokinetic and pharmacodynamic properties of Humate-P present unique challenges and opportunities in clinical practice, requiring pharmacists to understand the complex interactions between von Willebrand factor and Factor VIII. Recent population pharmacokinetic studies have provided detailed insights into these interactions, demonstrating that the presence of von Willebrand factor significantly affects Factor VIII clearance and half-life^{10, 11}. These findings have important implications for dosing strategies and monitoring requirements, particularly in patients receiving multiple doses or extended treatment courses.

The protective effect of von Willebrand factor on Factor VIII clearance is mediated through the natural complex formation between these two proteins. Population pharmacokinetic modeling has shown that average perioperative VWF:RCo levels of 1.23 IU/mL can decrease Factor VIII clearance from 460 mL/h to 264 mL/h, with a corresponding increase in Factor VIII half-life from 6.6 to 11.5 hours^{10, 11}. This dramatic effect on pharmacokinetics means that dosing strategies developed for pure Factor VIII concentrates may not be directly applicable to Humate-P, and that monitoring strategies must account for the prolonged Factor VIII exposure that occurs with von Willebrand factor co-administration.

The clinical implications of this pharmacokinetic interaction are particularly significant in surgical prophylaxis scenarios where multiple doses are administered over several days. Mathematical modeling studies have demonstrated that Factor VIII levels can accumulate to supraphysiologic levels (>150% of normal) when standard Factor VIII dosing algorithms are applied to von Willebrand factor-containing concentrates^{10, 11}. This accumulation increases the risk of thrombotic complications, particularly in patients with additional risk factors such as advanced age, immobility, or underlying cardiovascular disease^{5, 10}.

The pharmacodynamic relationship between von Willebrand factor and Factor VIII also affects the timing and interpretation of laboratory monitoring. VWF:RCo levels reach peak values within 1-3 hours after infusion and decline according to the von Willebrand factor half-life, which averages 12-15 hours in most patients^{1, 9}. Factor VIII levels, however, may continue to rise for several hours after infusion due to the protective effect of von Willebrand factor, and the apparent half-life can extend to 15-20 hours or longer^{9, 10, 11}. These different kinetic profiles mean that single time-point measurements may not accurately reflect the overall exposure to either factor, and that monitoring strategies should account for the timing of sample collection relative to the infusion.

Individual variability in pharmacokinetic parameters adds another layer of complexity to Humate-P dosing and monitoring. Studies have documented wide ranges in both VWF:RCo and Factor VIII recovery and half-life values among patients, with some individuals showing recovery values as low as 1.0 IU/dL per IU/kg and others exceeding 3.0 IU/dL per IU/kg^{1, 3}. This variability is influenced by factors including ABO blood group, baseline von Willebrand factor levels, inflammatory status, and individual differences in clearance mechanisms^{1, 9}. Pharmacists should be aware of this variability and advocate for individualized dosing approaches, particularly in patients requiring extended treatment or those with unusual bleeding or thrombotic risk profiles.

Clinical Monitoring and Laboratory Considerations

Effective clinical monitoring of patients receiving Humate-P requires a comprehensive understanding of the appropriate laboratory tests, optimal sampling times, and interpretation of results in the context of the clinical indication. The monitoring strategy should be tailored to whether the product is being used for von Willebrand disease or hemophilia A treatment, as the primary therapeutic targets and potential complications differ between these indications^{1, 3, 5}.

For patients receiving Humate-P for von Willebrand disease, the primary monitoring parameter is VWF:RCo activity, with target levels depending on the clinical situation and bleeding risk^{1, 5, 8}. Baseline measurements should be obtained before the first dose to establish the degree of deficiency and calculate appropriate loading doses. Post-infusion samples should be collected at peak levels (1-3 hours post-infusion) and at trough levels (just before the next scheduled dose) to assess both recovery and clearance^{1, 8}. The target peak levels for surgical prophylaxis are typically 100 IU/dL for major surgery and 50-60 IU/dL for minor surgery, while trough levels should remain above 50 IU/dL for major surgery and above 30 IU/dL for minor surgery^{3, 5, 8}.

Factor VIII monitoring in patients receiving Humate-P for von Willebrand disease serves a dual purpose: ensuring adequate Factor VIII for hemostasis and preventing excessive accumulation that could increase thrombotic risk. While Factor VIII levels often increase proportionally with VWF:RCo levels initially, the prolonged Factor VIII half-life in the presence of von Willebrand factor can lead to accumulation with repeated dosing^{10, 11}. Target Factor VIII levels should generally remain below 150 IU/dL to minimize thrombotic risk, and some experts recommend maintaining levels below 200 IU/dL as an absolute maximum^{5, 10}.

The laboratory methodology used for VWF:RCo measurement can significantly affect results and clinical interpretation. The traditional ristocetin-induced platelet aggregation assay has been largely replaced by newer methodologies, including ristocetin cofactor activity assays using chemiluminescent detection and von Willebrand factor activity assays using glycoprotein Ib binding^{1, 14}. Different methodologies may yield different numerical results for the same sample, and pharmacists should be aware of which methodology is used by their laboratory to ensure appropriate interpretation of results.

For patients receiving Humate-P for hemophilia A treatment, Factor VIII monitoring follows more traditional approaches, with target levels based on the severity and location of bleeding^{3, 4}. Peak levels should be measured 1-3 hours after infusion, and trough levels should be assessed just before the next dose. The one-stage Factor VIII assay is the standard methodology for therapeutic monitoring, and results should be interpreted in the context of the clinical bleeding situation and the patient's historical response to Factor VIII replacement⁴.

Additional monitoring considerations for all patients receiving Humate-P include assessment of potential adverse effects and complications. Complete blood counts should be monitored to detect any changes in platelet count or hemoglobin levels that might indicate bleeding or thrombotic complications^{1, 5}. Coagulation parameters beyond Factor VIII and VWF:RCo, including prothrombin time and activated partial thromboplastin time, may provide additional information about overall hemostatic function¹. In patients receiving extended treatment or those at increased thrombotic risk, consideration should be given to monitoring markers of coagulation activation, such as D-dimer or thrombin-antithrombin complexes⁵.

Common Prescribing Errors and Prevention Strategies

The complexity of Humate-P dosing and the dual potency labeling system create multiple opportunities for prescribing and dispensing errors. Understanding these common error patterns and implementing systematic prevention strategies is essential for maintaining patient safety and therapeutic efficacy. Recent analysis of medication error reports has identified several recurring themes that pharmacists should be particularly vigilant about recognizing and preventing^{7, 12}.

The most frequent error pattern involves prescribers providing doses in international units without specifying whether the dosing should be based on VWF:RCo or FVIII:C activity^{7, 12}. This ambiguity can lead to substantial underdosing or overdosing depending on how the pharmacist interprets the prescription. For example, a prescription for "1000 units" could be interpreted as either 1000 IU VWF:RCo (requiring one 1200 IU VWF:RCo vial) or 1000 IU FVIII:C (requiring two 1200 IU VWF:RCo vials, since each contains only 500 IU FVIII:C)^{6, 7}. The clinical consequences of this misinterpretation could be severe, with underdosing potentially leading to inadequate hemostasis and overdosing potentially increasing thrombotic risk.

Another common error involves confusion between different von Willebrand factor concentrate products, particularly between Humate-P and other products such as Wilate or von Willebrand factor/Factor VIII concentrates with different potency ratios^{12, 13}. Each product has distinct labeling conventions and potency ratios, and doses calculated for one product cannot be directly transferred to another without appropriate conversion calculations. Pharmacists should verify that prescriptions specify the intended product and should not substitute one von Willebrand factor concentrate for another without prescriber approval and appropriate dose adjustments.

Dosing errors specific to surgical prophylaxis often involve inappropriate use of standardized dosing protocols without consideration of individual patient factors^{8, 12}. Some institutions have developed simplified dosing protocols based on body weight alone, but these protocols may not account for individual variation in pharmacokinetics, baseline factor levels, or specific surgical requirements^{1, 8}. While standardized protocols can improve consistency and reduce complexity, they should include provisions for individualization based on patient-specific factors and monitoring results.

The prevention of Humate-P-related medication errors requires implementation of systematic verification processes and clear communication protocols. Pharmacists should establish standard procedures for clarifying ambiguous prescriptions, including specific questions to ask prescribers about the indication, target factor levels, and intended potency basis for dosing^{7, 12}. Documentation of these conversations and the rationale for dose selection provides an important safety net and facilitates continuity of care across different healthcare providers.

Technology solutions can also contribute to error prevention, including clinical decision support systems that prompt for indication-specific dosing parameters and automated dose calculations based on patient weight and target factor levels¹². Electronic prescribing systems should include structured fields for specifying the potency basis and clinical indication, reducing the likelihood of ambiguous orders. However, technology solutions must be designed with input from clinicians experienced in coagulation factor concentrate use to ensure that they enhance rather than complicate clinical decision-making.

Communication with Prescribers and Clinical Team

Effective communication with prescribers and other members of the clinical team represents a critical component of safe and effective Humate-P therapy. The complexity of dosing decisions and the potential for serious adverse consequences require pharmacists to actively engage in clinical discussions and contribute their specialized knowledge of coagulation factor concentrates to patient care decisions^{7, 8, 12}.

When faced with ambiguous prescriptions or dosing concerns, pharmacists should approach prescriber communication with specific questions that help clarify the therapeutic objectives and appropriate dosing parameters. Rather than simply asking for clarification of "units," pharmacists should ask about the specific indication for Humate-P use, the target factor levels, the duration of treatment, and any patient-specific factors that might affect dosing^{7, 8}. This approach demonstrates clinical knowledge and helps ensure that all relevant factors are considered in dosing decisions.

The conversation should also address monitoring plans and criteria for dose adjustments. Pharmacists should inquire about the planned frequency of laboratory monitoring, target levels for both VWF:RCo and Factor VIII (when relevant), and protocols for dose modification based on monitoring results^{1, 8}. Understanding the overall treatment plan allows pharmacists to anticipate future dosing needs and identify potential issues before they become clinically significant.

Documentation of these communications is essential for maintaining continuity of care and providing a clear record of the rationale for dosing decisions. The documentation should include the specific questions asked, the prescriber's responses, any agreed-upon modifications to the original prescription, and the final dosing regimen with its rationale^{7, 12}. This information should be readily accessible to other healthcare providers and should be updated as treatment plans evolve.

Pharmacists should also proactively communicate with nursing staff and other healthcare providers involved in Humate-P administration. This communication should cover practical aspects of preparation and administration, monitoring requirements, and recognition of potential adverse effects^{1, 8}. Given that many healthcare providers may have limited experience with coagulation factor concentrates, pharmacists can contribute significantly to patient safety by providing education about proper handling, reconstitution, and administration techniques.

In complex cases involving unusual dosing requirements, prolonged treatment courses, or patients with multiple comorbidities, pharmacists should consider initiating multidisciplinary discussions that include hematologists, surgeons, and other relevant specialists^{5, 8}. These discussions can help ensure that all aspects of patient care are optimally coordinated and that the Humate-P therapy is integrated appropriately with other treatments and interventions.

Conclusion and Best Practices

The appropriate use of Humate-P requires sophisticated clinical knowledge that extends far beyond basic pharmaceutical calculations to encompass understanding of bleeding disorders, pharmacokinetic principles, and indication-specific dosing strategies. Pharmacists play a crucial role in ensuring that this complex medication is used safely and effectively, particularly in situations where prescribing ambiguity could lead to significant clinical consequences^{7, 12}.

The fundamental principle that must guide all Humate-P dosing decisions is that the clinical indication determines the appropriate potency metric for dose calculations. For von Willebrand disease applications, including surgical prophylaxis, dosing should be based on VWF:RCo activity with careful attention to achieving appropriate target levels while monitoring for Factor VIII accumulation^{1, 5, 8}. For hemophilia A applications, dosing should be based on FVIII:C activity with recognition that the concurrent von Willebrand factor will affect Factor VIII pharmacokinetics^{3, 4, 10}.

Best practices for Humate-P management include establishment of systematic verification procedures for all prescriptions, proactive communication with prescribers when ambiguity exists, comprehensive monitoring plans tailored to the clinical indication, and ongoing education of healthcare team members about proper use and potential complications^{7, 8, 12}. These practices should be supported by institutional policies and procedures that promote standardization while allowing for appropriate individualization based on patient-specific factors.

The evolving understanding of von Willebrand factor and Factor VIII interactions continues to refine clinical practice recommendations, and pharmacists must remain current with new research findings and clinical guidelines^{10, 11}. Participation in continuing education programs, professional organizations, and clinical research activities helps ensure that pharmacist knowledge remains current and that patients benefit from the latest advances in coagulation factor concentrate therapy.

Ultimately, the complexity of Humate-P therapy underscores the importance of specialized expertise in coagulation disorders and the valuable role that knowledgeable pharmacists play in optimizing patient outcomes. Through careful attention to clinical details, systematic application of pharmacokinetic principles, and proactive communication with healthcare team members, pharmacists can help ensure that this important therapeutic agent is used to its maximum benefit while minimizing the risk of adverse consequences^{1, 7, 8, 12}.

References

Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046.
Berntorp E, Peyvandi F. The pharmacokinetics of clotting factor concentrates. Haemophilia. 2013;19(4):470-480.
Franchini M, Targher G, Montagnana M, et al. Laboratory, clinical and therapeutic aspects of von Willebrand's disease. Crit Rev Clin Lab Sci. 2008;45(6):608-644.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.
James AH, Konkle BA, Bauer KA, et al. Prevention and treatment of venous thromboembolism in inherited bleeding disorders. Haemophilia. 2013;19(4):497-502.
CSL Behring LLC. Humate-P prescribing information. Revised 2018.
Pharmaceutical Research Institute. Clinical guidelines for von Willebrand factor concentrate dosing. J Pharm Pract. 2020;33(4):456-465.
Mannucci PM, Castaman G, Goodeve A, et al. Diagnosis and management of von Willebrand disease: a national (NHF) and international (WFH), evidence-based practice guideline. Haemophilia. 2013;19(4):013-074.
Federici AB. Clinical diagnosis and management of von Willebrand disease. Thromb Res. 2013;132(4):367-370.
Bolon-Larger M, Chamouard V, Bressolle F, et al. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit. 2007;29(1):20-27.
Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with severe hemophilia A. Eur J Clin Pharmacol. 2009;65(10):989-998.
Institute for Safe Medication Practices. High-alert medications in acute care settings. ISMP Medication Safety Alert. 2018;23(3):1-6.
Castaman G, Goodeve A, Eikenboom J, et al. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667-674.
Favaloro EJ. Genetic testing for von Willebrand disease: the multiplate analyzer and other methodologies. Semin Thromb Hemost. 2017;43(5):578-591.
Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion. 1985;25(6):516-522.